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ABSTRACT
Urticarial rash, one of the clinical manifestations characteristic of cryopyrin-associated periodic syndrome
(CAPS), is caused by a mutation in the gene encoding for NLRP3 (nucleotide-binding oligomerization domain,
leucine-rich repeats containing family, pyrin domain containing 3). This intracellular pattern recognition receptor
and its adaptor protein, called apoptosis associated speck-like protein containing a caspase-recruitment and
activating domain (ASC), participate in the formation of a multi-protein complex termed the inflammasome. The
inflammasome is responsible for activating caspase-1 in response to microbial and endogenous stimuli. From
the analysis of cellular mechanisms of urticarial rash in CAPS, we have traced caspase-1 activated IL-1β in
CAPS to a surprising source: mast cells. Recently, two groups have generated gene-targeted mice that har-
bored Nlrp3 mutations. These mice had very severe phenotypes, with delayed growth and the development of
dermatitis, but not urticaria. The reason for the differences in the skin manifestations observed with CAPS and
these knock-in mice relates to the findings that the inflammasome also plays a role in contact hypersensitivity,
and that IL-18, another cytokine involved with inflammasome-activation of caspase-1, may be a major player in
dermatitis development.
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INTRODUCTION
The skin is the primary interface between the interior
of the body and the external environment. The skin
functions to retain water, prevent the permeation or
loss of other molecules and maintain body tempera-
ture. The skin also physically protects us from micro-
bial invasion. Furthermore, it has become established
that the skin itself plays a major role in the immune
system.1
Recognition of invading microorganisms is essen-
tial for inducing an effective immune response. This
process is mediated by germ line-encoded pattern
recognition receptors, which can also be found in
plants that do not have circulating white blood cells.
To date, the most extensively studied pattern recogni-
tion receptors have been the Toll-like receptors
(TLRs). Using their leucine-rich repeats (LRRs),
these transmembrane proteins recognize conserved
bacterial constituents, such as lipopolysaccharide
(LPS). More recently, another class of pattern recog-
nition receptors, called nucleotide-binding oligomeri-
zation domain (NOD)-LRRs containing family
(NLRs), have been identified.2 While TLRs detect
bacterial products at the outer cell surface or in en-
dosomes, intracellular NLRs mediate cytoplasmic rec-
ognition of bacterial products.3
Several NLR members participate in the formation
of a multi-protein complex termed the inflammasome
that is responsible for activating caspase-1 in re-
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Fig. 1 The inflammasome is comprised of an NLR protein 
and an adaptor protein ASC, which can bridge the NLR to 
pro-caspase-1. Activation of the inflammasome results in 
self-cleavage and activation of pro-caspase-1 into the active 
protease. Then, activated caspase-1 cleaves its target mole-
cules, including pro-IL-1β, into biologicaly active forms. 
LRRs, leucine-rich repeats; NOD, nucleotide-binding oligo-
merization domain; PYD, pyrin domain; CARD, caspase-re-
cruitment and activating domain; NLRP3, NOD-LRRs 
containing PYD 3; ASC, apoptosis-associated speck-like 
protein containing a CARD.
sponse to microbial and endogenous stimuli.4,5 The
inflammasome is comprised of an NLR protein and an
adaptor protein called apoptosis associated speck-like
protein containing a caspase-recruitment and activat-
ing domain (ASC), which can bridge the NLR to pro-
caspase-1 (Fig. 1). Activation of the inflammasome re-
sults in self-cleavage and activation of pro-caspase-1
into the active protease. Then, activated caspase-1
cleaves its target molecules, including pro-IL-1β, into
biologically active forms.6-9 IL-1β participates in sys-
temic and local responses to infection, injury and im-
munological challenges by inducing fever, activating
lymphocytes and by promoting leukocyte infiltrations
at sites of injury or infection.10,11
In this review, we will discuss the functions of the
inflammasome in the skin. In particular, we will focus
on the inflammasome comprised of NLR family, pyrin
domain containing 3 (NLRP3) in the regulation of IL-
1β production and the implications for skin diseases.
URTICARIA
Urticaria, or hives, is a common disease that affects
up to 20% of the general population at least once dur-
ing their lifetimes.12 This allergic disorder involving
the skin is fleeting in nature, as it is characterized by
the sudden appearance of wheals but the returning to
its normal appearance without pigmentation, usually
within 1-24 hours.13 In its histological aspects, the
wheal consistently exhibits localized edema of the
dermis with dilatations of the post-capillary venules
and lymphatic vessels. However, perivascular infil-
trates show variable intensities comprised of neutro-
phils, andor eosinophils, macrophages and T cells.13
These inconsistent histological findings may under-
line the complex nature of the pathogenesis of urti-
caria, which has many sources including histamine
release by activated mast cells.
Although patients with acute urticaria often com-
plain of an upper airway infection, the eliciting cause
is unclear in over 50% of patients. In particular, for
chronic urticaria, defined as that persisting longer
than 6 weeks, triggers remain unidentifiable in the
majority of cases, despite extensive clinical and labo-
ratory investigations.12 In addition, urticaria is some-
times triggered by cold or heat contact, solar expo-
sure, delayed pressure, mechanical stimuli and vibra-
tion. These subtypes of urticaria are classified as
physical urticaria. Other types of urticaria are aqua-
genic, cholinergic, evoked by a contact irritant or
exercise-induced.13 Moreover, 2 or more different
subtypes of urticaria can co-exist in any given patient.
Compared with the variety of proposed causes for
urticaia, the strategy for treatment is relatively sim-
ple. Histamine H1-receptor antagonists are recom-
mended as the first line of treatment because hista-
mine release by cutaneous mast cells plays an impor-
tant role in the development of urticaria. However,
good responses using oral antihistamines have only
been recorded for 40% of patients.12 Antihistamines
have been shown not to be effective for physical urti-
caria, suggesting that in a significant number of indi-
viduals, chronic urticaria is mediated via histamine-
independent mechanisms.
CRYOPYRIN-ASSOCIATED PERIODIC SYN-
DROME
An urticarial rash (Fig. 2) that develops in the neona-
tal or early infant period is one of the clinical manifes-
tations characteristic of cryopyrin-associated periodic
syndrome (CAPS). CAPS is caused by a mutation in
the gene encoding for NLRP3, previously known as
NALP3CIAS1cryopyrin.14,15 CAPS includes a spec-
trum of hereditary periodic fever disorders that com-
prise 3 phenotypically overlapping, but relatively dis-
tinct syndromes: familial cold antoinflammatory syn-
drome [FCAS, Mendelian inheritance in men number
(MIM) #120100], Muckle-Wells syndrome (MWS,
MIM #191900) and chronic infantile neurological cu-
taneous and articular (CINCA) syndrome (MIM
#607115), also known as neonatal-onset multisystem
inflammatory disease. FCAS and MWS are character-
ized by periodic attacks of urticarial rash, fever and
arthralgia; whereas patients with CINCA syndrome,
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Fig. 2 Urticarial rash in a CAPS patient with an R260W 
mutation in NLRP3. The eruption is non-pruritic and returns 
to its normal appearance without pigmentation. Histopa-
thological sample from a skin eruption shows edema in the 
dermis accompanied by the perivascular infiltration of inflam-
matory cels, predominantly neutrophils.
Table 1 Clinical manifestations of cryopyrin-associated 
periodic syndromes
CINCAMWSFCAS
++++++Skin rash
Arthritis/Arthritis/Arthritis?Joint involvement
ArthralgiaArthralgia
+++--Cartilage target
+++++-Deafness
++++?-Chronic meningitis
++++-Eye involvement
?+++Amyloidosis
FCAS, familial cold auto-inflammatory syndrome; MWS, 
Muckle-Wels syndrome; CINCA, chronic infantile neurological, cu-
taneous and articular syndrome.
the most severe form of CAPS, exhibit chronic urti-
caria, as well as fever, arthropathy, chronic meningi-
tis, papilledema, growth and mental retardation and
hearing loss (Table 1).16 The urticarial rash observed
in CAPS is similar to that associated with common ur-
ticaria. However, unlike ordinary urticaria, the rash
observed in most CAPS patients is not pruritic and re-
sponds to therapy with an IL-1 receptor antagonist
rather than antihistamines.17-19
INFLAMMASOME ACTIVATION IN MAST
CELLS
After development of an anti-IL-1β specific antibody
(canakinumab), it was found that patients with CAPS
have abnormally high levels of circulating IL-1β, ap-
proximately 5 times the normal amount.20 In addition,
treating patients with canakinumab relieved their
rashes within a day, suggesting that IL-1β was the
sole cytokine responsible for the skin eruptions in
CAPS. The disease-responsible gene, NLRP3, is pre-
dominantly expressed in monocytes, granulocytes
and chondrocytes.14 However, after performing im-
munohistochemical staining, we traced IL-1β in CAPS
to a surprising source: mast cells.21 Interestingly,
mast cells in the skin samples from CAPS patients ex-
pressed active IL-1β without any treatment, whereas
those from healthy donors only expressed active cy-
tokine when appropriately stimulated.
Primary mast cells derived from mouse bone mar-
row and human cord blood expressed inflammasome
components, including NLRP3 and its adapter protein
ASC. As was the case with macrophages, production
of mature IL-1β via the NLRP3-inflammasome in mast
cells required 2 signals. Microbial ligands, such as
LPS, trigger the synthesis of the IL-1β precursor. A
second ATP-triggered signal activates the inflamma-
some. Although a major function of LPS is to induce
pro-IL-1β production, LPS also promotes the expres-
sion of Nlrp3 in mast cells.
In macrophages, ATP-driven stimulation via the pu-
rinergic receptor P2X, ligand-gated ion channel 7
(P2RX7) is essential for caspase-1 proteolytic cleav-
age and IL-1β secretion by LPS-primed cells (Fig.
3).22,23 P2RX7 forms a non-selective ion channel upon
activation with ATP and, after stimulation, mediates
K+ efflux, which may be important for activating the
inflammasome.24 This ion channel mediated by
P2RX7 rapidly transforms to a pore-like structure by
recruiting a pannexin-1 pore that allows passage of
molecules as large as 900 Da.22 It is possible, as has
been proposed for macrophages,25 that ATP pro-
motes passage of microbial ligands, such as LPS, via
pannexin-1 to trigger inflammasome activation in
mast cells. Consistent with this conjecture, ATP alone
did not induce IL-1β secretion by mast cells, even
though ATP triggered large-pore formation. IL-1β se-
cretion by mast cells was blocked for cells derived
from P2rx7-deficient mice or by incubation in high K+
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Fig. 3 P2RX7 forms a non-selective ion channel upon acti-
vation by ATP. Upon stimulation, P2R7X mediates K+ eflux 
and rapidly transforms to a pore-like structure by recruiting a 
pannexin-1 pore, which alows passage of molecules as 
large as 900 Da.
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Pro-caspase-1
Caspase-1
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Fig. 4 Autoinflammatory disease-associated mutations in 
NOD2 and NLRP3. Crohn’ sdisease-associated mutations 
found primarily in the LRRs of NOD2 result in a loss of activ-
ity, whereas mutations associated with Blau syndrome and 
early onset sarcoidosis (EOS) clustered in the NOD region 
of NOD2 cause constitutive activation of the molecule. Un-
controled constitutive activation of NLRP3 in FCAS, MWS 
and CINCA are found in the NOD region of NLRP3. The mu-
tations in NOD2 and NLRP3 associated with autoinflamma-
tory diseases shown here are those found from our 
experience with cases and those mutations shown in bold 
are in analogous positions in the two proteins of NOD2 and 
NLRP3. 
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D382E
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extracellular medium. Thus, ATP-driven P2RX7 and
K+ efflux are also required for effective IL-1β secre-
tion by mast cells.21
CAPS-ASSOCIATED NLRP3 INDUCES URTI-
CARIA
Disease-associated mutations associated with CAPS
are localized to the centrally located NOD region in
NLRP3. Of note, similar missense mutations in NOD2
have been identified in patients with Blau syndrome,
another autosomal-dominant autoinflammatory syn-
drome, and early-onset sarcoidosis, a set of sporadic
granulomatous disorders that phenotypically resem-
ble Blau syndrome.26-28 Interestingly, the amino acids
affected by an R260W mutation in NLRP3 and an
R334W mutation in NOD2 are at analogous sequence
positions, suggesting a common molecular mecha-
nism for their roles in the development of autoinflam-
matory disease (Fig. 4). Via molecular interactions of
their LRRs with their own NOD regions, NLRP3 and
NOD2 are maintained in inactive conformations. This
is relieved by ligand recognition via the LRRs.29,30
Disease-associated mutations are thought to mimic
active conformational changes that are induced by
microbial ligands, and in vitro studies suggest that
these mutations exert gain-of-function effects.5,29 In
the case of NLRP3, in addition of NF-κB activation,
the mutation found in CAPS constitutively activates
caspase-1 to produce active IL-1β.
Mouse Nlrp3 mutants, corresponding to those ob-
served in human CAPS, induced constitutive Asc-
dependent NF-κB activation and IL-1β secretion.21
Transfer of mast cells expressing an R258W mutant,
corresponding to R260W of human CAPS-associated
NLRP3, induced perivascular neutrophil-rich inflam-
mation in mouse skin, a histological hallmark of the
urticaria observed in CAPS patients. These findings
are consistent with a previous report that showed en-
hanced production of IL-1β in the skin of CAPS pa-
tients.18
However, it remains unclear why mast cells with a
constitutively activated NLRP3-inflammasome pro-
duce mature IL-1β, even in the absence of LPS. One
possibility is that CAPS-associated NLRP3 mutants in-
duce pro-IL-1β via constitutive activation of NF-κB in-
duction.31,32 Another possibility is that production of
pro-IL-1β is induced by endogenous or environmental
cues that operate in the skin independently of
NLRP3. Consistent with this latter model, the charac-
teristic skin rash observed in CAPS often develops
within the first few weeks of life when the skin is first
Inflammasome in Skin Diseases
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exposed to environmental factors. This may include
exposure to small amounts of LPS andor other mi-
crobial stimuli. The observation that skin abnormali-
ties in incontinentia pigmenti (MIM #308300) com-
mence at birth33 is also consistent with this possibil-
ity. This disorder is an X-linked dominant inherited
disorder caused by a mutation of NEMO, a gene that
encodes the regulatory component of the I-κB kinase
complex responsible for activating the NF-κB signal-
ing pathway.
Collectively, inflammasome activation in mast cells
contributes to the pathogenesis of IL-1β-mediated dis-
eases of the skin. Mast cells reside in numerous tis-
sues and also participate in experimental models of
arthritis34 and encephalomyelitis.35,36 Thus, it is possi-
ble that these cells play a role in disease pathogene-
sis not only in the skin, but also in the joints and cen-
tral nervous system, which are also major diseased
sites in CAPS patients.16 Additional studies are
needed in order to better understand the contribu-
tions of mast cells to IL-1β-mediated diseases associ-
ated with NLRP3.
Furthermore, urticaria that is associated with
CAPS is usually non-pruritic and unresponsive to anti-
histamines. This clinical observation is in line with
experimental results that NLRP3-inflammasome acti-
vation induces IL-1β secretion, but not degranulation,
in mast cells. Nonetheless, mast cells that expressed
a CAPS-associated NLRP3 mutant promoted vascular
permeability, a cellular response critical for wheal for-
mation in vivo. Because many cases of non-CAPS ur-
ticaria are unresponsive to histamine H1-receptor an-
tagonists, it is possible that skin rash associated with
histamine resistance is mediated via inflammasome
activation in mast cells. Thus, understanding the
pathophysiology of CAPS may provide critical in-
sights into more common diseases, such as
antihistamine-refractory urticaria.
CAPS AND KNOCK-IN MICE
Recently, two groups37,38 have generated gene-
targeted mice harboring Nlrp3 mutations that mimic
the amino acid substitutions in NLRP3 that were
found to cause disease susceptibility in CAPS. The
mice generated in both studies had very severe phe-
notypes. Newborn mice with an R258W mutation in
Nlrp3 exhibited delayed growth, decreased weight
gain and increased mortality. Adult animals were in-
fertile and developed dermatitis, but not urticaria, as-
sociated with increased sizes of lymphoid organs.38
The mice with A350V in Nlrp3 died between days 2
and 14 and exhibited profound growth delays, skin
abscesses, and hair growth and pigmentation de-
fects.37
At the cellular level, despite the observation that T
cells in mutant mice displayed altered polarization
profiles favorable to Th17, both groups found that
this defect was due to the expression of the mutated
Nlrp3 in antigen-presenting cells (APCs), but not in T
cells. They isolated bone marrow-derived macro-
phages or dendritic cells (DCs) and explored their re-
sponses to TLR ligands in the presence or absence of
ATP. In contrast to a study of CD14-positive periph-
eral mononuclear cells from a human CAPS patient
that secreted IL-1β without any treatment,30 myeloid
cells from mutant mice in both studies did not sponta-
neously secrete mature IL-1β. Rather, they displayed
a considerably higher sensitivity to TLR ligands than
cells from wild type (WT) mice.37,38 Importantly, for
optimal activation, addition of exogenous ATP was
not required in order to release IL-1β, supporting the
notion that the mutated Nlrp3 was constitutively ac-
tive and, therefore, did not require additional stimuli
for inflammasome activation.
An important outcome from these knock-in mice
was that a common feature evoked by CAPS-
associated Nlrp3 was the development of severe skin
lesions. These included erythema, abscesses, scaling
and thickening of both the epidermis and dermis.
However, these observations only recapitulated
some, but not all, of the urticaria-like skin lesions re-
ported in CAPS patients. Moreover, both studies still
failed to address the critical question of whether or
not TLR-dependent accumulation of pro-IL-1β was
necessary for the burst of IL-1β secretion in CAPS.
CONTACT HYPERSENSITIVITY
The reasons for the discrepancies between the skin
manifestations of CAPS and gene-targeted mice har-
boring the Nlrp3 mutations could be directed to find-
ings that the inflammasome also plays a role in con-
tact hypersensitivity. Contact hypersensitivity in-
volves the priming of naïve T cells after sensitizing
chemicals penetrate the skin surface (sensitization)
and primed T cells are activated upon re-exposure to
the antigen (elicitation). Elicitation can be further
subdivided into early and late phases.39 The early
phase, characterized by increased vessel permeability
and local edema, peaks 8 hours after antigen re-
exposure and is believed to be mediated by local re-
lease of mediators, including IL-1β and histamine.40
The late phase develops 12-36 hours after antigen re-
exposure and is due to cellular infiltration. During
these processes, DC migration, antigen presentation,
expansion of specific T cells and recruitment of T
cells to the skin depend on the coordinated interac-
tions of inflammatory cytokines, namely IL-1β and IL-
18,41 which are important cytokines for initiating spe-
cific T-cell-mediated immune responses.
A role for the inflammasome in contact hypersensi-
tivity was analyzed by Watanabe et al.42 who found
that key components of the inflammasome were pre-
sent in keratinocytes. Some contact sensitizers, such
as trinitrochlorobenzene (TNCB), can induce
caspase-1-mediated cleavage and activation of IL-1β
and IL-18 in an ASC-dependent manner. Interestingly,
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chemical irritants like SDS and physical agents like
ultraviolet B could also trigger inflammasome activa-
tion in keratinocytes.43,44 Subsequently, it was found
that mice lacking Nlrp3 and adaptor protein Asc-
deficient mice had impaired early phase reactions
during the challenges. Thus, the inflammasome can
modulate the early effector phase of T cell-mediated
immune responses.
These findings, however, are in contrast with a re-
port by Sutterwala et al.45 who found that impaired re-
sponses in Nlrp3- and Asc-deficient mice were seen in
late-phase. Interestingly, in this report, Nlrp3-
deficient mice that received cells from sensitized WT
animals showed almost normal ear swelling, whereas
WT mice that received cells from sensitized donors
lacking Nlrp3 failed to develop ear swelling. This sug-
gests that Nlrp3 is necessary for inducing antigen-
specific T-cell responses. Indeed, Langerhans cell mi-
gration and an optimal contact hypersensitivity re-
sponse require functional caspase-1,46 even though
recent data suggest that important cross-presenting
APCs in the skin are not Langerhans cells, but are
langerin+CD103+ DCs, most likely of dermal ori-
gin.47,48
NECROSIS AND NLRP3
How can we explain the discrepancies in these two
reports on contact hypersensitivity in mice? One pos-
sibility is that TNCB is very potent when causing di-
rect tissue damage, and that the signaling involved
might be strong enough to overcome the require-
ment of inflammasome activation for T-cell priming.49
Of potential interest is a recent report showing that
necrosis directly activates the NLRP3 inflamma-
some.50,51 By treating human monocytic THP-1 cells
with indirubin oxime derivative 7-bromoindirubin-3’-
oxime, Li et al.50 showed that the NLRP3 inflamma-
some was activated in cells undergoing necrosis, re-
sulting in the production of mature IL-1β and IL-18. It
is remarkable that inflammasome activation and the
release of these caspase-1 targeting cytokines did not
require LPS priming or other pro-inflammatory stim-
uli.
Along these lines, the activation of NLRP3 itself
mediates a form of necrosis termed pyronecrosis.52,53
We previously showed that the expression of a
disease-associated mutation of NLRP3 resulted in a
caspase-1 independent, but cathepsin B-dependent
form of cell death.32 This characteristic cell death can
also be observed in monocytes derived from CAPS
patients. NLRP3-mutant monocytes rapidly and selec-
tively underwent necrosis-like programmed cell
death after treatment with LPS accompanied by the
induction of NLRP3 expression. This unique NLRP3
phenotype enabled us to differentiate NLRP3-mutated
cells from WT cells in CAPS patients who had
disease-associated mutant NLRP3 as a latent mosa-
icism.54
Pyronecrosis is caspase-independent; neither the
activating cleavage of effector caspase-3 nor its sub-
strate poly-(adenosine diphosphate ribose) polym-
erase (PARP) occurs during cell death. Pyronecrosis
proceeds in the presence of caspase-1-specific inhibi-
tors, and even pan-caspase inhibitors. However, cell
death is abrogated in the presence of CA074-Me, an
inhibitor of the lysosomal protease cathepsin B, impli-
cating the contribution of lysosome activity in the
pathway. Pyronecrotic cells do not demonstrate DNA
fragmentation or a loss of mitochondrial membrane
potential. By electron microscopy, the morphological
changes characteristic of pyronecrosis are consistent
with necrosis and include membrane degradation and
uncondensed chromatin. Similar to classic necrosis,
pyronecrosis is accompanied by the release of the im-
mune modulator high-mobility group box 1
(HMGB1). Pyronecrosis induced by NLRP3 activa-
tion suggests an exciting connection between cell
death and inflammation in response to cellular insult
to injury.
However, we should note that necrosis does not al-
ways induce inflammasome activation. Treatment
with hydrogen peroxide or paclitaxel, which induce
caspase-independent necrosis, fails to induce inflam-
masome activation. Similarly, induction of necropto-
sis through TNF-α in the presence of caspase-3 and
caspase-9 inhibitors55 did not result in inflammasome
activation. If necrosis was induced too rapidly by re-
peated cycles of freeze-thaw or excessive osmotic
shock, inflammasome activation was greatly reduced.
Based on these findings, during activation of the
NLRP3 inflammasome, the dissolution of the cellular
architecture that occurs during some specific forms
of necrosis may be required for lysosome destabiliza-
tion.56
Another impressive point to remember from the
study by Li et al.50 is that it remains unclear how pro-
IL-1β is induced in a sterile environment without bac-
terial components like LPS. Several endogenous dan-
ger signals released by necrotic cells have been
shown to stimulate TLRs and other pattern recogni-
tion receptors and, therefore, have the potential to in-
duce pro-IL-1β, although this has not been defini-
tively demonstrated. Of note, endogenous molecules
can serve a priming role for NLRP3-inflammasome
activation.51 Biglycan and hyaluronic acid, compo-
nents of the extracellular matrix, were capable of
priming macrophages for Nlrp3-inflammasome activa-
tion in response to pressure-disrupted necrotic cells.
Hence, extracellular matrix components that accumu-
late in non-physiological sites or amounts can func-
tion as signal for the induction of pro-IL-1β accumula-
tion, suggesting that inflammasome activation can oc-
cur in vivo in sterile settings without microbes.
Another possibility is that inflammasome activation
during necrosis can lead to the release of mature IL-
18, even in the absence of microbial stimuli, as IL-18
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is constitutively expressed by several cell types. IL-
18, in turn, via activation of the MyD88-dependent
pathway, leads to the transcription of pro-
inflammatory cytokine genes, including IL-1β,57 and
amplifies inflammation. Thus, IL-18 may be one of the
earliest mediators of the sterile inflammatory re-
sponse that is triggered by necrosis or tissue dam-
age.
IL-18 AND DERMATITIS
In a report by Watanabe et al.,42 IL-1 receptor defi-
ciency resulted in a significant decrease in the inten-
sity of ear swelling. However, it did not totally abro-
gate ear swelling after elicitation with TNCB, sug-
gesting that other cytokinessignals are likely to
modulate the early phases of contact hypersensitivity.
This may be due, at least in part, to the presence of
IL-18, which is also activated by caspase-1.58,59
Keratinocytes constitutively produce both pro-IL-
1β60 and pro-IL-18,61 but lack endogenous caspase-1
activity under normal conditions.60 Using established
keratinocyte-specific caspase1-transgenic mice with a
human keratin 14 promoter that specifically ex-
pressed the targeted gene at the basal layer of kerati-
nocytes, Yamanaka et al.62 showed that the mice
spontaneously suffered from chronic dermatitis un-
der specific pathogen-free (SPF) conditions, which
was accompanied by abnormally elevated serum lev-
els of IL-18 and IL-1β. Another transgenic mouse
model in which epidermal cells over secreted IL-18
also spontaneously developed atopic dermatitis-like
skin eruption under SPF conditions, and a deletion of
Il18 protected against the development of skin erup-
tions.63 This finding suggests that excessive cutane-
ous IL-18 release is a causative factor for the develop-
ment of dermatitis. Of potential interest is that the
phenotypes in the skin of these caspase-1 and IL-18
transgenic mice closely resembled that in disease-
associated Nlrp3 knock-in mice.
Furthermore, Terada et al.64 developed an intrinsic
atopic dermatitis mouse model with daily applications
of protein A, a surface molecule and virulence factor
of Staphylococcus aureus, which resulted in destruc-
tion of the skin barrier with a subclinical dose of SDS.
In this model, neutralizing anti-IL-18 antibodies and
Il18-deficient mice could completely protect against
SDS plus S. aureus-derived protein A-induced derma-
titis, suggesting the importance of IL-18 for atopic
dermatitis-like skin eruptions. This is also interesting
when we consider the recent findings that hemo-
lysins and bacterial lipoproteins in S. aureus can in-
duce activation of the NLRP3 inflammasome.65,66
Thus, another target inflammasome-activating cy-
tokine, IL-18, may be a major player for dermatitis de-
velopment.
LESSONS FROM CAPS
During the past decade, our understanding of the cel-
lular and molecular mechanisms by which innate im-
mune system molecules sense specific molecular pat-
terns of components of invading organisms has in-
creased tremendously. The NLRs, together with the
TLRs, are now appreciated as parts of this important
sensing system that allows the host to generate effec-
tive immune responses. NLRP3 also detects various
endogenous, sterile danger signals in the absence of
microbial infection. Progress in understanding the
roles of NLRs will improve our knowledge to answer
questions, such as how to transfer insights from
mouse model systems to translational research focus-
ing on human pathology, especially from the rare ge-
netic disorder CAPS, associated with an NLRP3muta-
tion, to more common diseases, such as ordinary urti-
caria and dermatitis. Interestingly, two NLRP3 single
nucleotide polymorphisms (SNP, rs4612666 and
rs10754558) were recently reported to be signifi-
cantly associated with susceptibility to food-induced
anaphylaxis as well as aspirin-induced asthma.67
Functional analysis of the rs4612666 SNP located in
intron 7 of NLRP3 showed 1.2-fold higher transcrip-
tional enhancer activity than the other constructs con-
taining the T allele, whereas rs10754558 in the 3’un-
translated region affected the stability of the NLRP3
mRNA. Thus, NLRP3 polymorphisms may increase
the risk of the hypersensitive phenotype of allergy.
However, we still cannot answer all of the ques-
tions for the roles of the inflammasome in the skin.
IL-18, as well as IL-33, are target molecules for in-
flammasome-activated caspase-1. Nevertheless, why
does the urticarial rash in CAPS depend solely on IL-
1β? Why can’t we induce hives in mice, even if acti-
vated Nlrp3 is induced? We should still look carefully
at the clinical manifestations of CAPS in order to de-
termine what happens in humans when the inflamma-
some is activated.
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